LG CNS, an AX specialist company, is stepping up its digital healthcare business with Cha Bio Group.

It is making an equity investment in Cha Biotech (085660), the holding company of Cha Bio Group, and pushing ahead with AI-based digital healthcare services and platform development. LG CNS signed a strategic partnership agreement with Cha Biotech on Jan. 14 at the Cha Bio Complex in Pangyo, Seongnam, Gyeonggi Province, for a 10 billion won equity investment and cooperation on AX and DX businesses.

Cha Bio Group has medical and biotech affiliates centred on Cha Biotech, including Cha AI Healthcare, CMG Pharmaceutical, Cha Vaccine Institute, Cha Healthcare and Cha Meditech. It also operates hospitals and medical businesses overseas, including in the United States, Singapore, Australia and Japan.

Through the investment, LG CNS will set up a regular consultative body with Cha Bio Group and carry out key AX and DX projects. In the short term, it will work on a smart big data platform to integrate data along with a shift to cloud infrastructure across the group. It also plans to upgrade infrastructure for therapeutic production facilities on an AI basis and optimise production processes.

Over the mid to long term, the companies will jointly commercialise a specialised AI model-based connected healthcare service, a strategic business of Cha Bio Group. Specialised healthcare AI will analyse a range of health and lifestyle data generated at hospitals, living spaces and wearable devices, and automatically link follow-up measures if health risk signals are detected, including connections to medical staff, guidance on treatment and emergency response.

For this, LG CNS plans to build an sLLM specialised for healthcare using EXAONE, developed by the LG AI Research institute, and implement a big data platform that collects and manages medical, genetic and lifestyle data.

The companies are also reviewing ways to expand the connected healthcare service globally using Cha Bio Group’s overseas hospital network in the United States, Singapore, Australia and Japan. They will also explore the possibility of expanding into related industries based on data and experience accumulated during platform operations.

An LG CNS official said, "We will strengthen the competitiveness of our digital healthcare platform through cooperation with Cha Bio Group." The official added, "We will establish ourselves as a technology partner leading AI- and data-based healthcare innovation."